Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells

Mittal, Deepak, Caramia, Franco, Michiels, Stefan, Joensuu, Heikki, Kellokumpu-Lehtinen, Pirkko-Liisa, Sotiriou, Christos, Loi, Sherene, Smyth, Mark J. · 2016 · Cancer Research

Published version of a preprint

Abstract

The HER2/ErbB2 monoclonal antibody (mAb) trastuzumab is combined with chemotherapy as a standard-of-care for newly diagnosed HER2(+) breast cancer patients, but some patients treated with this combination therapy experience early relapse. Our analysis of data from a clinical trial evaluating the efficacy of chemotherapy plus/minus trastuzumab suggested that the magnitude of trastuzumab benefit on distant disease-free survival was higher for increasing expression of the IL21 receptor (IL21R). Therefore, we investigated a possible role for IL21 signaling in promoting HER2 mAb therapeutic efficacy. We found that IL21R-deficient mice and wild-type mice treated with a neutralizing anti-IL21 mAb were less susceptible to trastuzumab-like anti-ErbB2 therapy. Furthermore, IL21R expression on CD8(+) T cells, but not on natural killer cells, was required for optimal anti-ErbB2 mAb efficacy, and IL21 expression was enhanced in tumor-infiltrating CD4(+) T lymphocytes after anti-ErbB2 therapy. Finally, we found that administering recombinant IL21 in combination with anti-ErbB2 therapy was therapeutic against primary tumors and experimental metastases in mice. Collectively, our findings suggest that elevating IL21 signaling may enhance trastuzumab efficacy, thus constituting a novel candidate strategy to overcome trastuzumab resistance and improve patient survival. Cancer

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-1567

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 51 references

Cited by

See all 27

Metadata

Authors
Mittal, D., Caramia, F., Michiels, S., Joensuu, H., Kellokumpu-Lehtinen, P.-L., Sotiriou, C., Loi, S., & Smyth, M. J.
Affiliations
  • The University of Queensland (AU)
  • The University of Melbourne (AU)
  • Université Paris-Sud (FR)
  • University of Helsinki (FI)
  • 7Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland.
  • Université Libre de Bruxelles (BE)
Corresponding author
Smyth, Mark J.
Venue
Cancer Research
Published
2016-01-14
Volume
76
Issue
2
Pages
264-274
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2224619536
Cited by
27
References
51
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 5
FWCI
1.62
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
Funders
QIMR Berghofer Medical Research Institute
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
HER2-positive breast cancer, trastuzumab, IL-21, CD8+ T cells, trastuzumab resistance, tumor-infiltrating CD4+ T cells, combination chemotherapy, distant disease-free survival, metastasis
MeSH terms
Interleukin-21, Animals, Breast Neoplasms, Female, Humans, Interleukins, Mice, Inbred BALB C, Signal Transduction, CD8-Positive T-Lymphocytes, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-1567
The paper
Mittal, D., Caramia, F., Michiels, S., Joensuu, H., Kellokumpu-Lehtinen, P.-L., Sotiriou, C., Loi, S., & Smyth, M. J. (2016). Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-1567

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.